Dr.Kohli joined Khalifa University as an Assistant Professor in February 2022. She graduated from Aston University, UK with a PhD in Biomedical science and a distinction award for professional training in cellular pathology. During her doctoral studies, she conducted pre-clinical research on stem cells for regenerative treatments. She won 5 awards during her PhD including the best young investigator award at the European Orthopaedic Research Society (EORS) annual meeting in 2012.
After her PhD, she undertook postdoctoral work at a medical research charity called RAFT in London, where she invented and patented a novel biomaterial for bone defect healing. She currently serves as a scientific consultant on the start-up company commercialising her patent. She also started her own research group during this time, which focused on developing pre-clinical models for biomaterial testing.
In 2019, she joined Imperial College London as a research associate where she developed a whole new facility for preclinical testing of metallic implants. She also served as a guest lecturer at University of Chester, University of Leeds and Imperial College London.
During her academic and research career, she has supervised a number of BSc, MSc, and PhD research projects and served on various academic and professional committees. She is currently the guest editor of MDPI Special Issue "Bioceramics, Bioglasses and Gels for Tissue Engineering."
In 2021 she was selected as one of the 27 scientist leaders from Europe to participate in BSF fellowship for scientists looking to become enterpreneurs.
Dr. Kohli's lab conducts research that focusses on innovative solutions to unmet clinical needs by building the bridge between laboratory science and clinical translation. Her main research interests are in stem-cell secretome therapies, regenerative medicine and 3D biomaterials.
Musculoskeletal (MSK) pathologies are debilitating and among the leading causes of disability worldwide. The proposed project aims to find an innovative treatment for the current unmet clinical needs in MSK pathologies. This could take the form of allogenic or autologous therapy. The aim is to shift the current paradigms regarding the use of stem cells as regenerative treatments to a “cell-free” approach, thereby surpassing many limitations associated with the use of stem cell therapies.
Currently hiring a PhD student, and a post-doctoral fellow
